Compare Inovio Pharmaceuticals Inc (INO) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Teladoc Health Inc trades at $6.6 (market cap $1.24B). The key difference: Teladoc Health Inc is far larger — about 15.8× Inovio Pharmaceuticals Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | TDOC | |
|---|---|---|
Market Cap | $78.55M | $1.24B |
Sector | Health | Health |
52-Week High | $2.87 | $9.72 |
52-Week Low | $0.66 | $4.47 |
Enterprise Value | $49.56M | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
TDOC trades at $6.66, down 5.93% amid bearish technical signals and negative sentiment following a Q2 2026 revenue miss and lowered full-year guidance. The stock shows weak profitability with a net income margin of -7.13% but trades below book value with a P/B of 0.94. Recent news highlights multiple law firm investigations into potential securities violations, adding to investor concerns.
The outlook remains challenging with revenue pressures in the BetterHelp segment and ongoing losses, though cost controls in Integrated Care provide some support. Analyst consensus is mixed with a $8.88 price target but high hold ratings, indicating cautious optimism amid significant operational and legal risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
